BioSpace News Archive

Vyant Bio, Inc. today announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s proteome-wide, Artificial Intelligence (“AI”) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (“CDD”), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.

This software will significantly improve ease of use and enable both beginners and experts to get better data, faster. With a fresh new look, Aura 4.0 is a major release with significant new features and product enhancements.

New England Biolabs (NEB) recently launched the NEBNext Immune Sequencing Kits, available for either human or mouse samples, to nable B-cell and/or T-cell repertoire (BCR and/or TCR) analysis of infections.

Nanotechnology is used in medicine to manipulate the molecule and develop new materials and devices.

Rafarma Pharmaceuticals, Inc.OTC:(RAFA) and one of the world’s largest producers of precious metals, Krastsvetmet (Russia, Krasnoyarsk), discussed implementing a joint project to produce the most popular platinum-based chemotherapy drugs.

Protein engineering is a protocol used for production of unnatural polypeptides, these are done through modifying the naturally found amino acid sequences.

The global narcolepsy drugs market generated $2,429 million in 2018, and is projected to reach $5,360 million by 2026, growing at a CAGR of 10.3% from 2019 to 2026.

Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), today announced a new initiative with Drake University and Certintell to drive improved health outcomes and demonstrate the value of combining remote patient monitoring (RPM) and comprehensive medication management, including MedWise® Medication Safety Reviews (MSRs) throughout rural Iowa.

W. L. Gore & Associates (Gore), today announced that five-year results of the U.S. prospective, multicenter study (N = 63) of endovascular repair of iliac aneurysms using the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) were presented at the 2021 Society for Vascular Surgery Annual Meeting.

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its second quarter 2021 financial results after market close on Thursday, August 26, 2021.